Upcoming event

From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress of the European Association of Nuclear Medicine.
Visit us at booth #59!

Upcoming event

Other news

Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers

Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers

Klaudia Cybulska (postdoc radiochemistry) has written an article about Huntington's Disease. Abstra...

Read more

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...

Read more

First Patient Dosed with TLX250-CDx in Italy for ccRCC

First Patient Dosed with TLX250-CDx in Italy for ccRCC

The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...

Read more

RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013

RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013

Radboud Translational Medicine (RTM) is proud to announce its role as manufacturing partner for the...

Read more

Interested in a collaboration?

Contact us to discuss the possibilities.